| Name | Title | Contact Details |
|---|
BP Security Services unit 9 Beech business park,Tillington road, Hereford HR4 9QJ PHONE: 01432 343622 EMAIL: bpsecurityservices@live.co.uk SERVICES: .INTEGRATED SECURITY SYSTEMS .CCTV/IPTV INSTALLATION .ACCESS CONTROL SYSTEMS .INTRUDER DETEC...
Emmis Interactive is a Chicago, IL-based company in the Software and Internet sector.
Based at Sacramento, California, tab32 is the industry`s No 1 technology platform for dental electronic health records (dental DEM) software, dental practice management system (dental SPM) and open data warehousing. Providers use tab32 to track 9.3 million appointments, 7.3 million patients, and over 100 million x-rays, with over 1 million monthly patient commitments and $ 375 million annual income passing through the platform. The all-in-one cloud platform delivers comprehensive and engaging patient experiences across the care value chain, enabling dental practices to achieve long-term sustainable growth and profitability. With a management team of former researchers, data scientists and engineers from University of california, tab32 has pioneered many innovations in the market such as integrated text messaging, VoIP, electronic forms, mobile payments, cloud imaging and a standard model for open data sharing in the dental field.
Bibliotech is a Lincoln, MA-based company in the Software and Internet sector.
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.